A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sera Prognostics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 400 shares of SERA stock, worth $2,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Holding current value
$2,696
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.6 - $11.69 $611,279 - $1.28 Million
109,157 New
109,157 $646,000
Q2 2023

Aug 14, 2023

SELL
$3.0 - $3.98 $25,548 - $33,893
-8,516 Reduced 41.33%
12,087 $39,000
Q1 2023

May 15, 2023

BUY
$1.19 - $4.25 $24,517 - $87,562
20,603 New
20,603 $78,000
Q3 2022

Nov 14, 2022

BUY
$1.55 - $2.71 $19,464 - $34,032
12,558 New
12,558 $20,000

Others Institutions Holding SERA

About SERA PROGNOSTICS, INC.


  • Ticker SERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 29,596,900
  • Market Cap $199M
  • Description
  • Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...
More about SERA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.